Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC) - Wikidata - awgldk - TriplyDB

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)

http://www.wikidata.org/entity/Q35583816

about

Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis.Modeling the relationship between progression-free survival and overall survival: the phase II/III trial.Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats.Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.Design Issues in Randomized Clinical Trials of Maintenance Therapies.Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.How and when to use genetic markers for nonsmall cell lung cancer.A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.Nanoparticulation improves bioavailability of Erlotinib.Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials.Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.EGFR-blockade with erlotinib reduces EGF and TGF-β2 expression and the actin-cytoskeleton which influences different aspects of cellular migration in lens epithelial cells.Gefitinib NSCLC maintenance therapy Discovering drugs to overcome chemoresistance in ovarian cancers based on the cancer genome atlas tumor transcriptome profile.The efficacy and safety of standardized allergen-removed Rhus verniciflua extract as maintenance therapy after first-line chemotherapy in patients with advanced non-small cell lung cancer.Synthesis and Biological Evaluation of Novel Carbohydrate-Derived Derivatives of Erlotinib.

P2860

Q26778318-CBD2F046-374F-4BD3-9ADC-281AC82D88F2 Q28067306-7A269C5C-75C6-4321-829A-89FAE6EC8D5F Q30540860-AD5F9BA6-6331-496B-83E0-570C54C4DB7B Q34040130-0EFAD5CF-5516-4665-8ADA-05B4D14730D4 Q34563432-15CA9672-B7B2-4148-A722-CA4F5C3DFE34 Q35106391-4B098046-D2D0-45D1-A4E1-CF9896C9E381 Q36685458-E67E0DDF-1086-4375-9FF5-DD5AD832E4B4 Q36848078-6DA13ECB-67BF-4A64-8E7D-B7CBD5D7F3DB Q37377562-E4B611DF-00B1-46B4-B7D2-C6351AB7BD25 Q37588365-6353170D-2530-4E91-A379-C730278F3F6C Q38458343-25EF795F-4DDA-4E1A-8E76-15CE0D151E05 Q38701944-26BB4969-DCF5-45AE-BBA3-EF563308A82A Q38990822-F9FB1AE3-5504-4315-B500-556041C12622 Q39004424-05CEE6FA-A69A-4286-93C1-02F365942B58 Q39208743-5AB3A5B8-EBB4-4C67-96EB-A118338B14E2 Q39240787-6FB0E1A5-188A-4A49-902D-7BDBB99C47C5 Q42110330-FD007D94-706B-434D-A569-F1D13F4CFFDD Q49220207-8FB6E5BC-CA13-4084-8EF2-3A1A32B132E3 Q50788257-8230BA2C-3F9E-427E-A15C-68F0E68F3405 Q51202412-AD380D43-A04C-4C30-8289-6ED9A94E90EA

P2860

Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC)

http://www.wikidata.org/entity/Q35583816

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@ast

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@en

type

label

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@ast

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@en

prefLabel

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@ast

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@en

P1433

Q35583816-359C2F8B-1FD9-4343-B6A7-BA9F094D8C2D

P1476

Q35583816-D8DB17A5-0345-43FC-AC87-2E1CB08698D8

P2093

Q35583816-10F7CA6F-CA25-449C-8003-DA42F59ACAEB

Q35583816-64790CCC-35B0-474B-8874-0AE07E9506B0

Q35583816-67F6068D-9CCD-47EC-B1DE-9F469F29AE6D

Q35583816-8410EC3A-FCB2-4040-AF39-63F1B5226E98

Q35583816-CE830748-EA3A-428F-AF51-AABB68B004B9

Q35583816-E7528A47-0184-4E05-923E-E7027DBD3B2E

Q35583816-EAFBE330-3C32-4F55-96CE-51233DE03FD7

P2860

Q35583816-18A5B174-4383-4521-91E8-3A8B524EC208

Q35583816-260C4E39-73E2-46FF-8525-ABDE60A72571

Q35583816-29333EC1-9808-4D08-BF33-38C1E7F72BAC

Q35583816-2D298C8B-6F98-4BBA-B7BE-785672677583

Q35583816-2F952E6F-E89F-4CEF-90B8-D8EDB5AE33DA

Q35583816-4272B429-FD2A-464B-8E8C-FF400A480125

Q35583816-6BD8787D-8E8B-4937-8F1F-0539AAA777B2

Q35583816-6E6D23D5-1099-4CCA-8305-C7CA7E8B3E2F

Q35583816-990BE921-20FF-4835-A1C3-907FBC2F2027

Q35583816-9A89A782-F477-48C3-822E-14CCD8405779

P304

Q35583816-E1D7767F-7E5E-47AB-A18D-C8BC9DA74E4E

P31

Q35583816-B79CD20E-0B45-4A42-B7CD-A44C4AA65416

P356

Q35583816-85F96A67-B7EB-473E-A762-C22F21E8218A

P433

Q35583816-ACAB2F91-7B4D-4218-8FD6-9D8A363DA052

P478

Q35583816-A300E5ED-93EA-45C5-8BCA-92FE1176C2B2

P577

Q35583816-653D4800-FCB4-424C-B7FB-27D8AB68437A

P5875

Q35583816-5AAAE814-EF73-485E-AF95-12C85EAD57AE

P698

Q35583816-DBA46FFE-8515-4D4E-B5CA-6258CED2BB0F

P932

Q35583816-2C92C405-DFC7-4C30-8F7F-F21A1A7F27EE

P356

THEONCOLOGIST.2010-0257

P1433

P1476

Approval summary: erlotinib ma ...... small cell lung cancer (NSCLC)

@en

P2093

John R Johnson

http://www.w3.org/2001/XMLSchema#string

Martin H Cohen

http://www.w3.org/2001/XMLSchema#string

Rajeshwari Sridhara

http://www.w3.org/2001/XMLSchema#string

Richard Pazdur

http://www.w3.org/2001/XMLSchema#string

Robert Justice

http://www.w3.org/2001/XMLSchema#string

Shenghui Tang

http://www.w3.org/2001/XMLSchema#string

Somesh Chattopadhyay

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance therapy in advanced non-small cell lung cancer.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.

The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Erlotinib in lung cancer - molecular and clinical predictors of outcome.

Treatment paradigms for advanced stage non-small cell lung cancer in the era of multiple lines of therapy.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.

P304

1344-1351

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0257

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49674478

http://www.w3.org/2001/XMLSchema#string

P698

21148614

http://www.w3.org/2001/XMLSchema#string

P932

3227916

http://www.w3.org/2001/XMLSchema#string